Omeros (FRA:3O8) Debt-to-Asset : 0.63 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Debt-to-Asset?

Omeros's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.73 Mil. Omeros's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €212.10 Mil. Omeros's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €346.87 Mil. Omeros's debt to asset for the quarter that ended in Dec. 2023 was 0.63.

Omeros Debt-to-Asset Historical Data

The historical data trend for Omeros's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Debt-to-Asset Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

1.42

1.49

0.83

0.58

0.63

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.58	0.61	0.65	0.69	0.63

Competitive Comparison of Omeros's Debt-to-Asset

For the Biotechnology subindustry, Omeros's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Omeros's Debt-to-Asset falls into.

Omeros Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Omeros's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.732	+	212.1)	/	346.873
	=	0.63

Omeros's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.732	+	212.1)	/	346.873
	=	0.63

Omeros (FRA:3O8) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Omeros Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Omeros's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines